Keywords: GlaxoSmithKline, Theravance, Anoro Ellipta, COPD, Relvar, Allergan, Botox, Overactive bladder, Mylan, Qualaquin

Regulatory briefs from GSK/Theravance, Allergan and Mylan

Article | 19 December 2012

Print This

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX0 have submitted a New Drug Application to the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in